Indian Accounting Research Analyst, Trudence Capital Advisors

Nitin Mangal

Nitin Mangal is a Research Analyst with more than 15 years of experience in Indian equities. He is Pioneer of Corporate Governance and Accounting Research in Indian Market and has successfully developed product for Institutional Investors named as "Analysis Beyond Consensus" during his association with Edelweiss Securities Ltd, Mumbai. Later during the career, he has worked with Veritas Investment Research Corporation, Canada as Asia Consultant covering Indian and US equities. He has been profiled by leading financial newspapers such as Wall Street Journal, Business Standard etc

Indian Accounting Research Analyst

Glenmark Pharma: Approval for Covid-19 Oral Drug

Unlock 1 Ill-Effects: Boon for the Consumer Discretionary?

Covid-19: Dull Economic Package, Lock-Down 4.0 Consequences

Equity Bottom-Up

<p>Shares of <a href="https://www.smartkarma.com/entities/biocon-ltd" target="_blank" data-smartkarma-citation="entities:398:1" rel="noopener">Biocon Ltd (BIOS IN)</a> escalated almost by 5.5% on Tuesday, 14th July after the Drugs Controller General of India (DCGI) approved to market Itolizumab for treating moderate-severe Covid-19 patients. However, the tables turned quick when the National Task force rejected the drug to be included in the clinical management protocols for Covid-19, causing a disheartening plummet of over 7% since Thursday. Given the current pandemic situation, this roller-coaster ride has created a haze-like situation for the company, filled with uncertainties.</p>

Shares of Biocon Ltd (BIOS IN) escalated almost by 5.5% on Tuesday, 14th July after the Drugs Controller General of India (DCGI) approved to market Itolizumab for treating moderate-severe Covid-19 patients. However, the tables turned quick when the National Task force rejected the drug to be included in the clinical management protocols for Covid-19, causing a disheartening plummet of over 7% since Thursday. Given the current pandemic situation, this roller-coaster ride has created a haze-like situation for the company, filled with uncertainties.

Biocon Ltd

Biocon: Covid-19 Respite Uncertain